The Global Microcrystalline Cellulose as Pharmaceutical Excipient Market was valued at USD 689 Million in 2023 and is projected to reach USD 1299.02 Million by 2032, growing at a Compound Annual Growth Rate (CAGR) of 7.30% during the forecast period (2025–2032). This robust growth trajectory is being driven by surging global demand for solid oral dosage forms, increasing pharmaceutical manufacturing activity in emerging economies, and the expanding role of Microcrystalline Cellulose (MCC) as an indispensable excipient in tablet and capsule production worldwide.

Microcrystalline cellulose is an odorless, tasteless, porous white powder derived from wood pulp or refined cotton. Its exceptional binding, compressibility, and flow-enhancing properties make it the excipient of choice for pharmaceutical manufacturers across commercial drug production. As the pharmaceutical industry scales up to meet rising global health demands, the spotlight is firmly on the key producers who are driving quality, innovation, and supply chain reliability. In this blog, we profile the Top 10 Companies in the Microcrystalline Cellulose as Pharmaceutical Excipient Industry—a mix of global specialty chemical leaders, dedicated excipient manufacturers, and emerging Asian producers shaping the future of pharmaceutical formulation.

---

🕐 1. DuPont

Headquarters: Wilmington, Delaware, USA
Key Offering: Avicel® Microcrystalline Cellulose (MCC) for Pharmaceutical Applications

DuPont, through its Nutrition & Biosciences division, is widely regarded as the global benchmark in MCC production. Its flagship Avicel® brand is one of the most trusted and extensively referenced excipient grades in pharmaceutical formulation. DuPont’s MCC products are used in tablet compression, capsule filling, and wet granulation processes across the world’s leading drug manufacturers.

Key Strengths:

• Industry-leading Avicel® product portfolio with multiple particle size grades

• Extensive global regulatory approvals including USP, EP, and JP compliance

• Deep technical support and formulation expertise for pharmaceutical clients

Download FREE Sample Report:
Global Microcrystalline Cellulose as Pharmaceutical Excipient Market – View in Detailed Research Report

---

② 2. JRS Pharma (J. Rettenmaier & Söhne)

Headquarters: Rosenberg, Germany
Key Offering: VIVAPUR® Microcrystalline Cellulose, Co-processed Excipients

JRS Pharma is among Europe’s most prominent pharmaceutical excipient manufacturers, offering a comprehensive range of MCC grades under the VIVAPUR® brand. The company serves major pharmaceutical companies across Europe, North America, and Asia with products designed for direct compression, wet granulation, and extrusion-spheronization. JRS places considerable emphasis on consistent quality and sustainable raw material sourcing, which has helped it maintain a strong market position across regulated markets.

Key Strengths:

• Wide range of functional MCC grades for diverse formulation needs

• Strong sustainability commitment through responsible forestry sourcing

• ISO-certified manufacturing with full compliance across major pharmacopoeias

---

③ 3. Asahi Kasei Corporation

Headquarters: Tokyo, Japan
Key Offering: Ceolus™ Microcrystalline Cellulose

Asahi Kasei is Japan’s leading MCC manufacturer, with its Ceolus™ brand enjoying widespread recognition in both domestic and international pharmaceutical markets. The company has been particularly innovative in developing high-functionality MCC grades that offer superior compressibility, enabling pharmaceutical manufacturers to produce smaller, more effective tablet formulations. Asahi Kasei’s strong technical research background gives it a distinct advantage in developing next-generation excipient solutions.

Key Strengths:

• High-functionality Ceolus™ grades enabling tablet miniaturization

• Strong presence across Asia-Pacific pharmaceutical markets

• Active R&D pipeline focused on co-processed and specialty MCC grades

---

④ 4. Roquette Frères

Headquarters: Lestrem, France
Key Offering: MICROCEL™ Microcrystalline Cellulose, Co-processed Excipients

Roquette is a global leader in plant-based ingredients and pharmaceutical excipients. Its MICROCEL™ MCC line serves solid dosage form manufacturers seeking high-quality, consistently performing cellulose excipients. Roquette’s broad excipient portfolio, combined with its deep expertise in plant-based chemistry, enables it to offer comprehensive formulation support to pharmaceutical companies looking to optimize tablet and capsule performance. The company is particularly strong in the European and North American markets.

Key Strengths:

• Vertically integrated supply chain ensuring raw material consistency

• Comprehensive co-processed excipient range for advanced formulations

• Global manufacturing footprint with facilities in Europe, Asia, and the Americas

Download FREE Sample Report:
Global Microcrystalline Cellulose as Pharmaceutical Excipient Market – View in Detailed Research Report

---

⑤ 5. Sigachi Industries Limited

Headquarters: Hyderabad, India
Key Offering: HiCel® and AceCel® Microcrystalline Cellulose Grades

Sigachi Industries has emerged as one of India’s most recognized MCC manufacturers, supplying pharmaceutical-grade cellulose excipients to markets across Asia, Europe, and North America. The company manufactures MCC from both wood pulp and refined cotton, offering flexibility across different formulation requirements. Sigachi went public on Indian stock exchanges in 2021, underscoring significant investor confidence in its growth trajectory within the pharmaceutical excipient space.

Key Strengths:

• Dual raw material sourcing from wood pulp and refined cotton

• Competitively priced, export-oriented production model

• Growing customer base across regulated markets in the US, EU, and Japan

---

⑥ 6. Mingtai Chemical Co., Ltd.

Headquarters: Taichung, Taiwan
Key Offering: Microcrystalline Cellulose Powder for Pharmaceutical Use

Mingtai Chemical is a well-established Taiwanese manufacturer of MCC, with decades of production experience serving pharmaceutical companies across Asia and beyond. The company’s MCC products comply with key international pharmacopoeial standards and are used extensively in tablet and capsule manufacturing. Mingtai has built a reputation for reliable supply consistency and competitive pricing, making it a preferred supplier for mid-size pharmaceutical manufacturers in Asian markets.

Key Strengths:

• Extensive experience in pharmaceutical-grade MCC production

• Compliance with USP, BP, and JP pharmacopoeial standards

• Reliable supply chain catering to regional and global pharmaceutical clients

---

⑦ 7. Accent Microcell Pvt. Ltd.

Headquarters: Vadodara, India
Key Offering: Microcrystalline Cellulose PH Grades for Pharmaceutical Excipient Applications

Accent Microcell is a specialized Indian manufacturer focused exclusively on pharmaceutical-grade MCC production. The company offers a comprehensive range of MCC grades compliant with USP, BP, EP, and IP pharmacopoeias. Accent Microcell has been expanding its export footprint significantly, supplying its products to pharmaceutical companies across more than 30 countries. Its dedicated focus on MCC allows for deep technical expertise and customized product development to meet client-specific formulation requirements.

Key Strengths:

• Dedicated MCC manufacturer with focused technical capabilities

• Multi-pharmacopoeial compliance supporting global regulatory submissions

• Active export business spanning more than 30 countries across regulated and semi-regulated markets

---

⑧ 8. Anhui Sunhere Pharmaceutical Excipients Co., Ltd.

Headquarters: Anhui Province, China
Key Offering: Microcrystalline Cellulose Pharmaceutical Excipient Grades

Anhui Sunhere is one of China’s prominent pharmaceutical excipient manufacturers, with MCC forming a core part of its product portfolio. The company serves both the domestic Chinese pharmaceutical industry and international markets, benefiting from China’s rapidly expanding pharmaceutical manufacturing base. Sunhere’s production capabilities are supported by modern manufacturing infrastructure and quality systems aligned with international Good Manufacturing Practice (GMP) requirements.

Key Strengths:

• Strong domestic presence in China’s high-volume pharmaceutical market

• Modern GMP-compliant manufacturing facilities

• Competitive cost structure supporting both domestic and international supply

Get Full Report Here:
Global Microcrystalline Cellulose as Pharmaceutical Excipient Market – View in Detailed Research Report

---

⑨ 9. Shandong Guangda Technological Development Co., Ltd.

Headquarters: Shandong Province, China
Key Offering: Wood Pulp-Based Microcrystalline Cellulose for Pharmaceutical Use

Shandong Guangda is a significant Chinese producer of MCC derived primarily from wood pulp, serving pharmaceutical manufacturers both within China and in export markets across Southeast Asia, the Middle East, and South America. The company has invested steadily in production capacity and quality systems, positioning itself as a cost-effective supplier for pharmaceutical companies that require pharmacopoeial-compliant MCC at competitive price points. Its growing international certifications are expanding its reach into more regulated markets.

Key Strengths:

• Large-scale wood pulp-based MCC production capacity

• Competitive pricing supporting penetration of emerging pharmaceutical markets

• Expanding regulatory certification program targeting key export markets

---

👑 10. Wei Ming Pharmaceutical Co., Ltd.

Headquarters: Taiwan
Key Offering: Pharmaceutical-Grade Microcrystalline Cellulose Excipients

Wei Ming Pharmaceutical is a Taiwanese company with a solid track record in producing MCC and other pharmaceutical excipients for the regional and global market. The company’s products meet key international pharmacopoeial standards and are used across tablet and capsule formulation processes. Wei Ming has consistently focused on quality improvement and customer service, establishing long-term supply relationships with pharmaceutical manufacturers in Asia and other regions. Its stability in quality output makes it a reliable partner for drug companies with stringent regulatory requirements.

Key Strengths:

• Established track record in pharmaceutical excipient supply across Asia

• Consistent pharmacopoeial-compliant quality standards

• Long-term client relationships with regional pharmaceutical manufacturers

Get Full Report Here:
Global Microcrystalline Cellulose as Pharmaceutical Excipient Market – View in Detailed Research Report

---

🌎 Outlook: The Future of Microcrystalline Cellulose in Pharmaceuticals Is Innovation-Driven and Globally Expansive

The microcrystalline cellulose as pharmaceutical excipient market is undergoing a meaningful transformation. While established grades continue to dominate volume applications in tablet and capsule manufacturing, the industry is investing heavily in co-processed excipients, high-functionality MCC grades, and application-specific product development that addresses the increasingly complex demands of modern drug formulation. North America represented USD 202.70 million of the market in 2023 and continues to grow at a CAGR of 6.26%, reflecting the region’s strong pharmaceutical manufacturing base and regulatory rigor.

📈 Key Trends Shaping the Market:

• Rising demand for direct compression-compatible MCC grades driven by pharmaceutical manufacturing efficiency goals

• Accelerating growth in Asia-Pacific, particularly China and India, as regional pharmaceutical output expands

• Increasing adoption of co-processed excipients that combine MCC with other functional materials for superior tableting performance

• Growing regulatory scrutiny on excipient quality, driving investment in pharmacopoeial compliance and audit-ready supply chains

The companies profiled above are not only supplying the global pharmaceutical industry with a critical functional ingredient—they are actively shaping the next generation of pharmaceutical excipient science, enabling safer, more effective, and more manufacturable medicines for patients worldwide.